arrow
T

Thomas E. Hutson

Texas Tech University
H指数:75
被引数:5.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Exploring Health-Related quality of life across the disease spectrum in renal cell carcinoma: a conceptual domain analysis

探索肾细胞癌疾病谱中健康相关生命质量的领域分析

2025-10-010
OA
Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma

为转移性或局限性肾细胞癌患者开发健康相关生活质量问卷

2025-08-190
PRE
Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma

III期随机CLEAR试验的生物标志物分析:lenvatinib联合pembrolizumab与sunitinib治疗晚期肾细胞癌的比较

2024-12-012
OAAI
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study

在3期CLEAR研究的最终预设生存分析中,晚期肾细胞癌患者对Lenvatinib联合Pembrolizumab的反应特征

2024-07-012
OA
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms (vol 13, 1223282, 2023)
2024-03-010
OAAI
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

晚期肾细胞癌患者的3期CLEAR研究: lenvatinib + pembrolizumab和sunitinib亚组的结果

2023-08-1620
OAAI
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study

Lenvatinib联合Pembrolizumab与舒尼替尼治疗晚期肾细胞癌的国际转移性肾细胞癌数据库联盟亚组按反应深度和疗效的生存率: 3期随机CLEAR研究分析

2023-08-0110
OAAI
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920

nivolumab联合ipilimumab治疗晚期肾细胞癌脑转移患者的安全性和有效性: CheckMate 920

CANCER
IF5.1
2021-11-1632
OAAI
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial
2021-05-0124
OAAI
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
2021-04-081.1K
OA
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)
CANCER
IF5.1
2021-03-2542
OAAI